PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)

This early-phase study tests a personalized mRNA cancer vaccine (XH001) given alongside standard treatment after surgery for people with high-risk solid tumors (bile duct, gallbladder, pancreatic, liver, or stomach cancer). The main goals are to check safety and see if the vaccin…

This early-phase trial tests a new drug called MT-4561 in about 27 people with advanced solid tumors (like lung, breast, or pancreatic cancer) who have no standard options left. The main goals are to find a safe dose and see if the drug can shrink tumors. It is a first-in-human s…

This study tests a new drug called BMS-986523, alone or with other cancer drugs, in people with advanced solid tumors (like lung, colorectal, or pancreatic cancer) that have a specific genetic change (KRAS mutation). The goal is to see if it is safe and works. About 252 adults wi…

This study tests a new approach using immune cells from healthy donors, engineered to recognize and attack cancer cells. The target is chosen based on each participant's tumor profile. The trial includes 85 adults with advanced solid tumors that have not responded to standard tre…

This early-phase trial tests whether adding the drug fostamatinib to standard chemotherapy can help people with pancreatic cancer that can be removed by surgery. About 36 adults will receive the combination before and after their operation. The main goal is to see if the treatmen…

This early study tests a new treatment for pancreatic cancer that cannot be surgically removed. Ten participants will receive a single injection of a radioactive implant directly into their tumor, alongside standard chemotherapy. The main goals are to check if the procedure is sa…

This study tests a new oral drug called JYP0015 in adults with advanced solid tumors that have a RAS mutation, including pancreatic, lung, and colorectal cancers. The drug is designed to block multiple forms of the RAS protein, which can drive cancer growth. The trial aims to che…

This Phase 2 trial is testing an oral drug called RNK08954 in 60 people with metastatic pancreatic cancer that has a specific genetic change (KRAS G12D mutation). The drug is taken daily and aims to slow tumor growth. Researchers will measure how long the cancer stays under contr…

This study tests a new drug called BNT327 combined with standard chemotherapy in adults with metastatic pancreatic cancer that has not been treated before. The goal is to see if the combination shrinks tumors better than chemo alone. About 105 participants will be enrolled, and r…

This study tests an experimental drug called RMC-6236 in about 754 adults with advanced solid tumors (like lung, colon, or pancreatic cancer) that have specific RAS mutations. The main goal is to check the drug's safety and side effects, not to cure the cancer. Participants must …

This early-phase trial tests a new drug called ProAgio combined with standard chemotherapy (gemcitabine and nab-paclitaxel) and possibly an immunotherapy (atezolizumab) for people with advanced pancreatic cancer that has spread. The goal is to find a safe dose and see if the comb…

This study tests a new treatment using specially designed immune cells (CAR-NK cells) that target two markers on pancreatic cancer cells. It is for people with advanced pancreatic cancer that has spread or cannot be removed by surgery. The goal is to find a safe dose and see if t…

This study tests a new drug called daraxonrasib, which targets a specific protein (RAS) that helps cancer grow. It is given alone or with standard chemotherapy to people with metastatic pancreatic cancer that has spread. The goal is to see if it helps patients live longer or slow…

This early-phase study tests a new drug called STRO-004 in adults with advanced solid tumors that have not responded to standard treatments. The study has three parts: finding a safe dose of STRO-004 alone, testing that dose in more patients, and combining STRO-004 with another d…

This early-phase trial tests whether adding chemotherapy directly into the abdomen (intraperitoneal paclitaxel) to standard IV chemotherapy (NALIRIFOX) is safe and effective for adults with pancreatic cancer that has spread to the lining of the belly. Ten participants will receiv…

This program offers a personalized peptide vaccine, PCNAT-01, to eligible patients with pancreatic cancer who have had surgery and completed chemotherapy. The vaccine is designed to train the immune system to recognize and attack leftover cancer cells, potentially lowering the ch…

This study tests a new treatment using specially designed immune cells (CAR-NK cells) that target two markers on pancreatic cancer cells. The goal is to see if these cells are safe and can shrink tumors in people with advanced pancreatic cancer that has not responded to standard …

This study tests a mix of chemotherapy (NALIRIFOX), an immunotherapy drug (adebrelimab), and a special type of radiation (PULSAR) as a first treatment for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination is safe and …

This study looks at how the genetic makeup of pancreatic cancer affects response to a chemotherapy called FOLFIRINOX given before surgery. About 45 adults with non-metastatic pancreatic cancer will receive the chemo, then have their tumors analyzed to see if genetic subtypes (lik…

This phase 2 study tests an experimental drug called BT5528 in adults with metastatic pancreatic cancer that has spread and worsened after one prior treatment. The drug targets a specific protein on cancer cells. Researchers will measure how well it shrinks tumors and track side …

This study tests a new drug called KO-2806 in about 300 adults with advanced solid tumors that have not responded to standard treatments. The drug is given alone or with other cancer medicines. The main goals are to check safety and see if the drug can shrink tumors.

This study is testing a new way to find and treat several types of advanced solid tumors, including kidney, pancreatic, and colorectal cancers. It uses a special radioactive compound that attaches to a protein found on these cancer cells. The study has multiple parts: first, to s…

This study tests a new drug called RMC-5127, alone or with other medicines, in adults with advanced solid tumors (like lung, colorectal, or pancreatic cancer) that have a specific KRAS G12V mutation. The goal is to see if the drug is safe and can shrink tumors. About 574 particip…

This study tests whether adding the experimental drug atebimetinib to standard chemotherapy helps people with metastatic pancreatic cancer live longer. About 510 adults who have not had prior treatment will receive either the new combination or standard chemo alone. The goal is t…

This study tests whether adding an experimental drug called zoldonrasib to standard chemotherapy helps people with a specific genetic form of metastatic pancreatic cancer (KRAS G12D mutation) live longer without their cancer growing. About 670 adults with advanced pancreatic canc…

This study tests a new drug called MR001 combined with standard chemotherapy for people with advanced pancreatic cancer that has worsened after initial treatment. The goal is to find a safe dose and see if the combination can shrink tumors or slow the disease. About 45 adults wit…

This study is developing a blood test that looks for tiny genetic molecules called miRNAs, which can signal the presence of several gastrointestinal cancers like liver, pancreatic, and colorectal cancer. Researchers will analyze blood samples from 1,000 adults—half with cancer an…

This study is testing a new type of PET scan called FAPI PET to see if it can find pancreatic cancer progression or return earlier than current tests. About 35 adults with pancreatic cancer will get this scan along with their usual exams. The goal is to improve early detection an…

This phase 3 trial is testing whether a new radioactive dye called [18F]FAPI-74, used with a PET/CT scan, can better detect if pancreatic cancer has spread to other parts of the body. About 200 adults with pancreatic cancer will receive one dose of the dye and then be scanned. Re…

This study tests a new technology called NEO-Match® that measures the stiffness of pancreatic tissue from a biopsy sample. Researchers want to see if this test can predict how well a patient will respond to cancer treatment and help diagnose pancreatic cancer more accurately. Abo…

This study tests a special medical food powder (Encala®) in 18 adults with pancreatic cancer who have trouble absorbing fat, causing stomach issues and weight loss. The goal is to see if the powder is easy to take and helps improve fat absorption and quality of life. This is an e…

This study aims to understand why liver metastases are so deadly in colorectal and pancreatic cancers. Researchers will analyze tumors and blood from 625 participants to find new targets for immune and gene therapies. The goal is to develop better treatments for these hard-to-tre…